Delving into the Latest Updates on Clinical Supplies Management Europe SA with Synapse

Overview

Tags

Congenital Disorders

Immune System Diseases

Hemic and Lymphatic Diseases

Recombinant coagulation factor

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

Recombinant coagulation factor	1

Top 5 Target	Count

vWFCP(ADAM metallopeptidase with thrombospondin type 1 motif 13)	1

一项评价 TAK-755（rADAMTS-13，也称为 BAX 930/SHP655）预防性治疗和按需治疗重度先天性血栓性血小板减少性紫癜（cTTP；Upshaw-Schulman 综合征或遗传性血栓性血小板减少性紫癜）受试者的安全性和疗效的 IIIb 期、前瞻性、开放性、多中心、单治疗组、延续研究

[Translation] A Phase IIIb, prospective, open-label, multicenter, single-arm, continuation study evaluating the safety and efficacy of TAK-755 (rADAMTS-13, also known as BAX 930/SHP655) as a preventive and on-demand treatment in subjects with severe congenital thrombotic thrombocytopenic purpura (cTTP; Upshaw-Schulman syndrome or hereditary thrombotic thrombocytopenic purpura)

主要目的：从治疗中出现的相关不良事件 (AE) 和严重不良事件 (SAE) 方面评价 TAK-755 (rADAMTS-13) 在预防性治疗队列和按需治疗队列中的长期安全性和耐受性。

[Translation]

Primary objective: To evaluate the long-term safety and tolerability of TAK-755 (rADAMTS-13) in both the preventive and on-demand treatment cohorts in terms of treatment-emergent adverse events (AEs) and serious adverse events (SAEs).

Start Date26 Jan 2022

Sponsor / Collaborator

Clinical Supplies Management Europe SA

[+3]

100 Clinical Results associated with Clinical Supplies Management Europe SA

Login to view more data

0 Patents (Medical) associated with Clinical Supplies Management Europe SA

Login to view more data

100 Deals associated with Clinical Supplies Management Europe SA

Login to view more data

100 Translational Medicine associated with Clinical Supplies Management Europe SA

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data